Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
immune suppressive human adipose-derived mesenchymal stem cells + hematopoietic stem cells
- Development stage
- Preclinical
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intrathecal, Intracerebroventricular
01
Overview
This is a combination cell therapy consisting of immune suppressive human adipose-derived mesenchymal stem cells (hAD-MSCs) and hematopoietic stem cells (HSCs). Mesenchymal stem/stromal cells are multipotent stromal cells derived from adipose tissue that possess immunomodulatory properties, including the ability to attenuate inflammation by modulating both innate and adaptive immune responses. Hematopoietic stem cells are responsible for the generation of all blood cell lineages and play a key role in reconstituting the hematopoietic system following injury or transplantation. The combination aims to leverage the immunosuppressive effects of hAD-MSCs with the regenerative capacity of HSCs, potentially enhancing therapeutic outcomes in conditions characterized by excessive inflammation or immune dysregulation. This approach is under investigation for various indications, including traumatic brain injury and other inflammatory or degenerative diseases[1].
- Other names
- immune suppressive human adipose-derived mesenchymal stem cells and hematopoietic stem cellsimmunosuppressive hAD-MSCs + HSCs
Beyond the preview
Go deeper on immune suppressive human adipose-derived mesenchymal stem cells + hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on immune suppressive human adipose-derived mesenchymal stem cells + hematopoietic stem cells.